Published in Science on November 24, 2005
Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma | NCT03071705
AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell (2008) 16.72
Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science (2010) 11.29
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature (2009) 10.59
Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol (2009) 10.18
The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer (2009) 8.43
AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. Proc Natl Acad Sci U S A (2007) 8.23
Regulation of the mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell (2010) 7.59
The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol (2011) 6.83
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
AMPK and PPARdelta agonists are exercise mimetics. Cell (2008) 6.39
Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov (2011) 5.79
Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest (2010) 5.39
AMP-activated protein kinase--development of the energy sensor concept. J Physiol (2006) 4.93
AMPK regulates the circadian clock by cryptochrome phosphorylation and degradation. Science (2009) 4.72
Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest (2007) 4.47
SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem (2008) 4.16
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab (2010) 4.08
Cellular and molecular mechanisms of metformin: an overview. Clin Sci (Lond) (2012) 4.04
A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell (2010) 4.02
Lkb1 regulates cell cycle and energy metabolism in haematopoietic stem cells. Nature (2010) 3.93
Metformin prevents tobacco carcinogen--induced lung tumorigenesis. Cancer Prev Res (Phila) (2010) 3.86
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85
Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature (2013) 3.72
Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. Am J Psychiatry (2013) 3.69
Molecular mechanisms of cancer development in obesity. Nat Rev Cancer (2011) 3.65
Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell (2011) 3.64
Time-restricted feeding without reducing caloric intake prevents metabolic diseases in mice fed a high-fat diet. Cell Metab (2012) 3.64
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62
The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature (2010) 3.55
Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature (2010) 3.54
AMP-activated protein kinase signaling in metabolic regulation. J Clin Invest (2006) 3.39
Lifespan extension induced by AMPK and calcineurin is mediated by CRTC-1 and CREB. Nature (2011) 3.32
AMPK and cell proliferation--AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol (2006) 3.11
Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest (2008) 3.11
Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature (2014) 3.09
Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation. Science (2010) 3.05
Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy. J Clin Invest (2011) 3.00
Chemical genetic screen for AMPKα2 substrates uncovers a network of proteins involved in mitosis. Mol Cell (2011) 2.99
Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism. Endocr Rev (2008) 2.96
LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) (2009) 2.94
Metformin induces a dietary restriction-like state and the oxidative stress response to extend C. elegans Healthspan via AMPK, LKB1, and SKN-1. PLoS One (2010) 2.81
Metformin inhibits cell proliferation, migration and invasion by attenuating CSC function mediated by deregulating miRNAs in pancreatic cancer cells. Cancer Prev Res (Phila) (2011) 2.77
Metformin and insulin suppress hepatic gluconeogenesis through phosphorylation of CREB binding protein. Cell (2009) 2.69
Metformin and other biguanides in oncology: advancing the research agenda. Cancer Prev Res (Phila) (2010) 2.60
Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase. J Biol Chem (2007) 2.54
Phosphorylation of LKB1 at serine 428 by protein kinase C-zeta is required for metformin-enhanced activation of the AMP-activated protein kinase in endothelial cells. Circulation (2008) 2.48
Activation of AMP-activated protein kinase in the liver: a new strategy for the management of metabolic hepatic disorders. J Physiol (2006) 2.47
Metformin and prostate cancer: reduced development of castration-resistant disease and prostate cancer mortality. Eur Urol (2012) 2.45
SNF1-related kinases allow plants to tolerate herbivory by allocating carbon to roots. Proc Natl Acad Sci U S A (2006) 2.40
AMPK and SIRT1: a long-standing partnership? Am J Physiol Endocrinol Metab (2010) 2.40
Metformin disrupts crosstalk between G protein-coupled receptor and insulin receptor signaling systems and inhibits pancreatic cancer growth. Cancer Res (2009) 2.36
Metabolic targets for cancer therapy. Nat Rev Drug Discov (2013) 2.32
Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem J (2014) 2.30
mTOR couples cellular nutrient sensing to organismal metabolic homeostasis. Trends Endocrinol Metab (2011) 2.28
Understanding the benefit of metformin use in cancer treatment. BMC Med (2011) 2.28
Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway. Proc Natl Acad Sci U S A (2010) 2.27
AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J Biol Chem (2010) 2.21
Structure of the LKB1-STRAD-MO25 complex reveals an allosteric mechanism of kinase activation. Science (2009) 2.13
AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol (Oxf) (2009) 2.13
Hormonal regulation of hepatic glucose production in health and disease. Cell Metab (2011) 2.12
Metformin inhibits the inflammatory response associated with cellular transformation and cancer stem cell growth. Proc Natl Acad Sci U S A (2012) 2.11
Metformin therapy and risk of cancer in patients with type 2 diabetes: systematic review. PLoS One (2013) 2.10
AMPK: Lessons from transgenic and knockout animals. Front Biosci (Landmark Ed) (2009) 2.09
Skeletal muscle-selective knockout of LKB1 increases insulin sensitivity, improves glucose homeostasis, and decreases TRB3. Mol Cell Biol (2006) 2.09
mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome. Proc Natl Acad Sci U S A (2009) 2.08
Cooperative interactions between CBP and TORC2 confer selectivity to CREB target gene expression. EMBO J (2007) 2.07
AMPK integrates nutrient and hormonal signals to regulate food intake and energy balance through effects in the hypothalamus and peripheral tissues. J Physiol (2006) 2.06
Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. Am J Physiol Endocrinol Metab (2005) 2.04
Validation of anti-aging drugs by treating age-related diseases. Aging (Albany NY) (2009) 2.01
Metformin: multi-faceted protection against cancer. Oncotarget (2011) 2.00
Pancreatic LKB1 deletion leads to acinar polarity defects and cystic neoplasms. Mol Cell Biol (2008) 1.96
AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci (2010) 1.95
PKA phosphorylates and inactivates AMPKalpha to promote efficient lipolysis. EMBO J (2009) 1.94
LKB1 is essential for the proliferation of T-cell progenitors and mature peripheral T cells. Eur J Immunol (2010) 1.94
Regulation of multisite phosphorylation and 14-3-3 binding of AS160 in response to IGF-1, EGF, PMA and AICAR. Biochem J (2007) 1.92
Metformin activates a duodenal Ampk-dependent pathway to lower hepatic glucose production in rats. Nat Med (2015) 1.91
Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev Res (Phila) (2012) 1.90
Energy metabolism in the liver. Compr Physiol (2014) 1.88
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: a replication and meta-analysis of five cohorts. Diabetologia (2012) 1.83
S-adenosylmethionine in liver health, injury, and cancer. Physiol Rev (2012) 1.82
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther (2011) 1.81
A fundamental system of cellular energy homeostasis regulated by PGC-1alpha. Proc Natl Acad Sci U S A (2007) 1.79
Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol (2009) 1.78
Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program. Diabetes (2008) 1.78
TAp63 is a master transcriptional regulator of lipid and glucose metabolism. Cell Metab (2012) 1.77
Metformin activates AMP kinase through inhibition of AMP deaminase. J Biol Chem (2010) 1.76
Crosstalk between insulin/insulin-like growth factor-1 receptors and G protein-coupled receptor signaling systems: a novel target for the antidiabetic drug metformin in pancreatic cancer. Clin Cancer Res (2010) 1.76
The orphan nuclear receptor Nur77 regulates LKB1 localization and activates AMPK. Nat Chem Biol (2012) 1.75
Adipocyte CREB promotes insulin resistance in obesity. Cell Metab (2009) 1.72
Molecular mechanism of action of metformin: old or new insights? Diabetologia (2013) 1.71
LKB1 regulates pancreatic beta cell size, polarity, and function. Cell Metab (2009) 1.70
Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci U S A (2011) 1.69
Developing a head for energy sensing: AMP-activated protein kinase as a multifunctional metabolic sensor in the brain. J Physiol (2006) 1.67
Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care (2011) 1.65
Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. FASEB J (2011) 1.65
Paracrine and endocrine effects of adipose tissue on cancer development and progression. Endocr Rev (2011) 1.65
Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERalpha negative MDA-MB-435 breast cancer model. Breast Cancer Res Treat (2008) 1.64
Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov (2012) 1.63
Potential applications for biguanides in oncology. J Clin Invest (2013) 1.63
Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest (2001) 23.21
TSC2 mediates cellular energy response to control cell growth and survival. Cell (2003) 20.21
Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med (2002) 14.15
AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab (2005) 13.91
Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. J Biol (2003) 12.91
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature (2001) 11.72
Metabolic control through the PGC-1 family of transcription coactivators. Cell Metab (2005) 11.66
LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. EMBO J (2004) 10.82
Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature (2003) 9.77
LKB1 is the upstream kinase in the AMP-activated protein kinase cascade. Curr Biol (2003) 9.14
CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature (2001) 8.44
Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. Cell Metab (2005) 8.30
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature (2004) 7.64
Ca2+/calmodulin-dependent protein kinase kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell Metab (2005) 7.15
The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature (2005) 7.14
The Anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways. J Biol Chem (2002) 6.36
The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem (2005) 6.27
Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation. Nature (2002) 6.10
Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev (2004) 5.00
The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression. J Clin Invest (2001) 4.93
The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell (2004) 4.91
Activation of yeast Snf1 and mammalian AMP-activated protein kinase by upstream kinases. Proc Natl Acad Sci U S A (2003) 4.87
PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med (2004) 4.64
Regulation of hepatic fasting response by PPARgamma coactivator-1alpha (PGC-1): requirement for hepatocyte nuclear factor 4alpha in gluconeogenesis. Proc Natl Acad Sci U S A (2003) 4.34
Evidence for 5' AMP-activated protein kinase mediation of the effect of muscle contraction on glucose transport. Diabetes (1998) 4.31
Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J (2005) 4.31
AMP-activated protein kinase plays a role in the control of food intake. J Biol Chem (2004) 3.84
Regulation of fasted blood glucose by resistin. Science (2004) 3.54
Elm1p is one of three upstream kinases for the Saccharomyces cerevisiae SNF1 complex. Curr Biol (2003) 3.31
Short-term overexpression of a constitutively active form of AMP-activated protein kinase in the liver leads to mild hypoglycemia and fatty liver. Diabetes (2005) 2.88
AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J Biol Chem (2004) 2.83
EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nat Genet (1993) 2.72
C75, a fatty acid synthase inhibitor, reduces food intake via hypothalamic AMP-activated protein kinase. J Biol Chem (2004) 2.39
The route of administration is a major determinant of the transduction efficiency of rat tissues by adenoviral recombinants. Gene Ther (1995) 2.39
Foxa2 integrates the transcriptional response of the hepatocyte to fasting. Cell Metab (2005) 2.15
Coordinate regulation of malonyl-CoA decarboxylase, sn-glycerol-3-phosphate acyltransferase, and acetyl-CoA carboxylase by AMP-activated protein kinase in rat tissues in response to exercise. J Biol Chem (2002) 2.11
The blooming of the French lilac. J Clin Invest (2001) 1.80
Pioglitazone treatment activates AMP-activated protein kinase in rat liver and adipose tissue in vivo. Biochem Biophys Res Commun (2004) 1.72
Long-term AICAR administration and exercise prevents diabetes in ZDF rats. Diabetes (2005) 1.71
CREB: the unindicted cancer co-conspirator. Trends Cell Biol (2005) 1.70
Function of mammalian LKB1 and Ca2+/calmodulin-dependent protein kinase kinase alpha as Snf1-activating kinases in yeast. J Biol Chem (2005) 1.64
Transforming activity of MECT1-MAML2 fusion oncoprotein is mediated by constitutive CREB activation. EMBO J (2005) 1.48
Activating AMP-activated protein kinase without AMP. Mol Cell (2005) 1.43
Metformin prevents the development of acute lipid-induced insulin resistance in the rat through altered hepatic signaling mechanisms. Diabetes (2004) 1.28
Snf1 kinase complexes with different beta subunits display stress-dependent preferences for the three Snf1-activating kinases. Curr Genet (2005) 1.25
Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science (2009) 49.82
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science (2007) 32.68
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature (2009) 19.65
The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature (2008) 18.20
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet (2006) 17.19
Scansite 2.0: Proteome-wide prediction of cell signaling interactions using short sequence motifs. Nucleic Acids Res (2003) 15.74
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci U S A (2004) 12.30
Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature (2006) 12.13
Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell (2002) 11.65
Large-scale characterization of HeLa cell nuclear phosphoproteins. Proc Natl Acad Sci U S A (2004) 10.78
Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest (2008) 10.74
Pyruvate kinase M2 is a phosphotyrosine-binding protein. Nature (2008) 9.77
Activated Kras and Ink4a/Arf deficiency cooperate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev (2003) 8.27
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2006) 8.26
Tuberous sclerosis complex gene products, Tuberin and Hamartin, control mTOR signaling by acting as a GTPase-activating protein complex toward Rheb. Curr Biol (2003) 8.25
Bidirectional transport of amino acids regulates mTOR and autophagy. Cell (2009) 7.88
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell (2004) 7.77
Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell (2003) 7.42
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell (2009) 7.39
Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell (2012) 7.36
The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature (2005) 7.14
The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain. Cell (2003) 7.04
Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates. Science (2003) 6.97
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature (2013) 6.53
High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A (2005) 6.35
Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proc Natl Acad Sci U S A (2005) 6.26
A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell (2009) 6.23
Pancreatic adenocarcinoma. N Engl J Med (2014) 6.21
Pancreatic cancers require autophagy for tumor growth. Genes Dev (2011) 6.17
A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat Med (2013) 6.09
Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A (2006) 5.90
Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. Science (2011) 5.73
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 5.73
Inhibition of pyruvate kinase M2 by reactive oxygen species contributes to cellular antioxidant responses. Science (2011) 5.72
A genetic screen for candidate tumor suppressors identifies REST. Cell (2005) 5.61
A PtdInsP(3)- and Rho GTPase-mediated positive feedback loop regulates neutrophil polarity. Nat Cell Biol (2002) 5.58
Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal (2009) 5.57
Evidence for an alternative glycolytic pathway in rapidly proliferating cells. Science (2010) 5.44
TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science (2003) 5.25
The mighty mouse: genetically engineered mouse models in cancer drug development. Nat Rev Drug Discov (2006) 5.11
Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res (2005) 5.07
A rapid method for determining protein kinase phosphorylation specificity. Nat Methods (2004) 5.04
Linking functional decline of telomeres, mitochondria and stem cells during ageing. Nature (2010) 5.02
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev (2004) 5.00
Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A (2002) 4.93
The CREB coactivator TORC2 functions as a calcium- and cAMP-sensitive coincidence detector. Cell (2004) 4.91
High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. Cancer Discov (2011) 4.78
Impaired regulation of hepatic glucose production in mice lacking the forkhead transcription factor Foxo1 in liver. Cell Metab (2007) 4.74
PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat Med (2004) 4.64
SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature (2011) 4.57
Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2. Nature (2007) 4.54
Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron (2007) 4.47
A fasting inducible switch modulates gluconeogenesis via activator/coactivator exchange. Nature (2008) 4.43
TORCs: transducers of regulated CREB activity. Mol Cell (2003) 4.42
Protein sequences from mastodon and Tyrannosaurus rex revealed by mass spectrometry. Science (2007) 4.41
Telomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice. Nature (2010) 4.36
Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell (2009) 4.30
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst (2005) 4.19
CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol (2011) 4.12
Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab (2010) 4.08
Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. Mol Cell (2010) 4.07
Hepatic glucose sensing via the CREB coactivator CRTC2. Science (2008) 4.05
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev (2010) 3.99
Rheb fills a GAP between TSC and TOR. Trends Biochem Sci (2003) 3.90
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
Oncogenic B-RAF negatively regulates the tumor suppressor LKB1 to promote melanoma cell proliferation. Mol Cell (2009) 3.85
Aberrant overexpression of satellite repeats in pancreatic and other epithelial cancers. Science (2011) 3.77
High-resolution characterization of the pancreatic adenocarcinoma genome. Proc Natl Acad Sci U S A (2004) 3.75
Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol (2002) 3.68
Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell (2011) 3.64
The Lkb1 metabolic sensor maintains haematopoietic stem cell survival. Nature (2010) 3.55
The Crohn's disease protein, NOD2, requires RIP2 in order to induce ubiquitinylation of a novel site on NEMO. Curr Biol (2004) 3.54
Lkb1 regulates quiescence and metabolic homeostasis of haematopoietic stem cells. Nature (2010) 3.54
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol (2012) 3.40
RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature (2012) 3.40
The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell (2003) 3.36
Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev (2009) 3.35
FoxO1 regulates multiple metabolic pathways in the liver: effects on gluconeogenic, glycolytic, and lipogenic gene expression. J Biol Chem (2006) 3.35
Lifespan extension induced by AMPK and calcineurin is mediated by CRTC-1 and CREB. Nature (2011) 3.32
cAMP promotes pancreatic beta-cell survival via CREB-mediated induction of IRS2. Genes Dev (2003) 3.32
TRB3 links the E3 ubiquitin ligase COP1 to lipid metabolism. Science (2006) 3.26
Feedback inhibition of Akt signaling limits the growth of tumors lacking Tsc2. Genes Dev (2005) 3.25
PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. J Clin Oncol (2009) 3.24
A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature (2012) 3.24